DEC 0 4 2002 M

Express Mail No.: EL 500

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Morré and Morré

Confirmation No.: 5585

Application No.: 09/536,551

Group Art Unit: 1617

Filed: March 28, 2000

Examiner: Wells, L.

For: METHODS FOR IDENTIFYING

Attorney Docket No.: 8951-124-999

AGENTS THAT INHIBIT SERUM AGING FACTORS AND USES AND

COMPOSITIONS THEREOF

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed on June 7, 2002 in connection with the above-identified patent application and in accordance with Rule 111 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit concurrently herewith (a) a copy of the claims as pending, attached hereto as Exhibit A and (b) a Petition for Extension of Time Under 37 C.F.R. § 1.136(a) for three months, extending the time for response up to and including December 7, 2002.

REMARKS

Claims 12 to 24 are pending in the instant application. A copy of the claims as pending is attached as Exhibit A.

THE REJECTION UNDER 35 U.S.C. § 112, FIRST PARAGRAPH, SHOULD BE WITHDRAWN

The Examiner has rejected claims 12 to 24 under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for antibodies, allegedly does not reasonably provide enablement for test substances. Applicants respectfully disagree.

In response, Applicants submit that the specification has provided sufficient guidance and direction to enable one of ordinary skill in the art to screen for agents that